Summit Therapeutics SMMT is also developing a dual PD-1 and VEGF inhibitor, ivonescimab, in collaboration with China-based Akeso. The company acquired an exclusive license from Akeso in 2022 to ...

The FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma (NPC) in adults. No trade name was indicated for the drug. The first ...

Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), targets neutrophil serine proteases, key mediators of neutrophilic inflammation. In a phase 3, double-blind trial ...

The article titled "Effects of the DPP-1 Inhibitor HSK31858 in Adults with Bronchiectasis in China (SAVE-BE): A Phase 2, Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial," focuses ...

with a unique binding mode from previously reported WRN inhibitors Phase 1 dose escalation trial ongoing in MSI-H solid tumors with GSK MSI-H prevalence has been reported at approximately 31%, 20%, ...

(RTTNews) - Actinium Pharmaceuticals, Inc. (ATNM) Tuesday has launched a clinical program evaluating Actimab-A in combination with the PD-1 inhibitors pembrolizumab - KEYTRUDA and nivolumab OPDIVO.

Flexible mRNA vaccine protects mice from deadly C. diff infections, including recurring cases PD-1 inhibitor therapies include blockbusters such as Merck’s Keytruda and Bristol Myers Squibb’s ...

Ron Lanton, Partner, Lanton Law, discusses why the regulatory body made the decision to place restrictions on PD-1 inhibitors for gastric cancers. PE: Can you explain the FDA’s reasoning behind ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. HSK31858 given as 20 mg or 40 mg performed better ...

and 57.1%, and ACR70 responses were 6.9%, 22.2%, and 31.7%. All analyses comparing SHR0302 vs placebo were highly significant (P < .0001). "This is the first highly selective JAK inhibitor ...

Eight months after becoming the first China-made PD-1 inhibitor to score an approval in the United States, Junshi and Coherus’ Loqtorzi (toripalimab) appears set up to win clearance in a second ...